APP and Alzheimer disease: Extensive therapeutic efficacy for AD has been attributed to MH84 (ethyl 2-(4,6-bis(4-(trifluoromethyl)-phenethoxy)pyrimidin-2-yl-thio)hexanoate), specifically it regulates β-secretase processing of APP via a PGC-1α-dependent mechanism, improving mitochondrial dysfunction and impacting AD progression [104].